Abstract:Objective: To analyze the effects of combined treatment with L-carnitine, recombinant human erythropoietin and iron on the clinical efficacy and complications of hemodialysis patients. Methods: 92 hemodialysis patients who were admitted to our hospital from May 2017 to May 2018 were selected and randomly divided into control group (n=46) and observation group (n=46) according to the random number table method; Recombinant human erythropoietin and iron were only given. Patients in the observation group were treated with levocarnitine, recombinant human erythropoietin, and iron; clinical efficacy was compared between the two groups. Results: After treatment, the incidence of complications in the observation group and the control group were 2.17% (1/46) and 15.22% (7/46), respectively. The difference between the two groups was statistically significant (χ2= 4.929, P<0.05). Before treatment, there was no significant difference in iron transgenic protein saturation, hematocrit, serum ferritin and hemoglobin between the two groups (P>0.05). The levels of the indicators in the observation group were compared with the control group. The differences between the two groups after treatment were compared, and the differences in improvement were not compared. There were significant differences between the two groups (t=7.107, 12.581, 38.529, 12.024; P<0.05); The levels of blood urea nitrogen, blood urea and serum creatinine were significantly lower in the patients after treatment than in the control group (t=8.855, 18.612, 37.383; P<0.05). Conclusion: The combination of levocarnitine, recombinant human erythropoietin, and iron in patients with hemodialysis complications can effectively improve the clinical symptoms of patients and promote the improvement of renal function. The incidence of adverse reactions is low, and the safety is high. Clinical promotion.
董海霞,吕玉风,张定武. 左卡尼汀重组人促红细胞生长素及铁剂联合治疗血液透析患者的疗效及并发症发生情况分析[J]. 河北医学, 2018, 24(11): 1867-1869.
DONG Haixia, LV Yufeng. Efficacy and Complications of Levocarnitine Recombinant Human Erythropoietin and Iron in Hemodialysis Patients. HeBei Med, 2018, 24(11): 1867-1869.